房颤抗凝患者缺血性卒中与系统性栓塞的残余风险:大规模真实世界数据(F-CREATE项目)
平均随访3年期间发生200例IS/SE(发病率0.57/100人年),高龄、高血压和血脂异常与IS/SE风险显著增加相关,可改变危险因素(高血压、糖尿病、血脂异常)归因于IS/SE风险的比例为30.0%。
要点
- 房颤抗凝患者中,高血压和血脂异常是IS/SE的独立危险因素。
- 可改变危险因素(高血压、糖尿病、血脂异常)归因于约30%的IS/SE残余风险。
- 高龄(65-74岁 vs <65岁)与IS/SE风险增加相关(调整HR 2.02)。
核心结论
- 在口服抗凝药的房颤患者中,约三分之一的IS/SE残余风险可归因于高血压、糖尿病和血脂异常等可改变危险因素。
主要发现
- 平均随访3年期间发生200例IS/SE,发病率为0.57/100人年。
- 多变量分析中,高龄(65-74 vs <65岁;调整HR 2.02,95%CI 1.49-2.73)、高血压(调整HR 1.41,95%CI 1.04-1.92)和血脂异常(调整HR 1.46,95%CI 1.07-1.98)与IS/SE风险增加显著相关。
- 可改变危险因素(高血压、糖尿病和血脂异常)归因于IS/SE风险的比例为30.0%(95%CI 16.1%-41.6%)。
临床怎么用
- 对口服抗凝药的房颤患者,应重视高血压、糖尿病和血脂异常等可改变危险因素的综合管理,以降低IS/SE残余风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Among patients with atrial fibrillation, the risks of ischaemic stroke and systemic embolism (IS/SE) are high even with effective anticoagulation. Using large-scale, real-world data from Japan, this study aims to clarify residual risks of IS/SE attributable to modifiable risk factors among patients with atrial fibrillation who are taking oral anticoagulants. METHODS: The study design we employed was a retrospective cohort. Health check-ups and insurance claims data of Japanese health insurance companies were accumulated from January 2005 to June 2017. We identified 11 848 participants with atrial fibrillation who were on oral anticoagulants during the study period. We set the modifiable risk factors as hypertension, diabetes and dyslipidaemia. A Cox proportional hazards model was used to obtain the effects of the risk factors for IS/SE. RESULTS: During an average of 3 years' follow-up, 200 cases of IS/SE occurred (incidence rate 0.57 per 100 person-years). In multivariable analyses, older age (65-74 vs <65 years; adjusted HR 2.02 (95% CI 1.49 to 2.73)), hypertension (adjusted HR 1.41 (1.04 to 1.92)) and dyslipidaemia (adjusted HR 1.46 (1.07 to 1.98)) were significantly associated with increased risk of IS/SE. Percentage of IS/SE risk attributable to modifiable risk factors (hypertension, diabetes and dyslipidaemia) was 30.0% (16.1% to 41.6%). CONCLUSION: Among patients with atrial fibrillation on anticoagulant therapy, approximately one-third of the residual risks were estimated to be attributable to modifiable risk factors such as hypertension, diabetes and dyslipidaemia.
引用
- Maeda T, Nishi T, Funakoshi S, et al. Residual risks of ischaemic stroke and systemic embolism among atrial fibrillation patients with anticoagulation: large-scale real-world data (F-CREATE project). Heart. 2020. PMID: 32817313. doi:10.1136/heartjnl-2020-317299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。